LOGIN  |  REGISTER
Astria Therapeutics

Revvity to Present at Upcoming Investor Conferences

April 30, 2025 | Last Trade: US$91.25 1.65 -1.78

WALTHAM, Mass. / Apr 30, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:

Bank of America Global Healthcare Conference 2025
Tuesday, May 13, 2025
9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer

Goldman Sachs 46th Annual Global Healthcare Conference
Tuesday, June 10, 2025
8:00 a.m. ET - Prahlad Singh, president and chief executive officer

Attendees will receive an update on the Company and its strategic priorities during fireside chats.

Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page